AIMT Market Cap History
Below is a table of the AIMT market cap history going back to 8/6/2015:

Date AIMT Market Cap
8/6/2015940.21M
8/11/2015972.16M
10/31/2015635.85M
2/26/2016715.10M
4/30/2016547.10M
7/31/2016506.63M
10/31/2016689.99M
3/10/20171.12B
4/28/2017978.66M
7/31/20171.09B
10/31/20171.48B
2/15/20181.97B
4/30/20181.80B
7/31/20181.69B
10/31/20181.56B
2/15/20191.51B
4/30/20191.26B
7/31/20191.21B
8/1/2019166.92M
10/31/20191.76B
2/14/20201.82B
4/30/20201.12B
7/24/2020950.34M

Also see: AIMT Shares Outstanding History
and AIMT YTD Return
AIMT Historical Market Cap:
+0.22% CAGR
AIMT Historical Market Cap: +0.22% CAGR

Mouse over chart for data details
8/6/2015 ...7/24/2020
Aimmune Therapeutics is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. Co.'s main therapeutic approach, which it refers to as Characterized Oral Desensitized Immunology Therapy (CODIT™), is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure or reduce symptom severity should an allergic reaction occur. PALFORZIA™ (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is Co.'s internally developed product utilizing CODIT and has been approved by the U.S. Food and Drug Administration and it is indicated for the mitigation of allergic reactions. We show 23 historical shares outstanding datapoints in our AIMT shares outstanding history coverage, used to compute AIMT market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing AIMT market cap history over the course of time is important for investors interested in comparing AIMT's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of AIMT versus a peer is one thing; comparing AIMT market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like AIMT can fluctuate over the course of history. With this page we aim to empower investors researching AIMT by allowing them to research the AIMT market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for AIMT:
AIMT SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aimmune Therapeutics (AIMT) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

AIQ Market Cap History
AKAO Market Cap History
AKBA Market Cap History
AKCA Market Cap History
AKER Market Cap History
AKRX Market Cap History
ALBO Market Cap History
ALC Market Cap History
ALDR Market Cap History
ALDX Market Cap History
More Healthcare companies »

 

AIMT Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.